The Hormone-Sensitive Prostate Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Hormone-Sensitive Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hormone-Sensitive Prostate Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hormone-Sensitive Prostate Cancer and features dormant and discontinued products.
GlobalData tracks 34 drugs in development for Hormone-Sensitive Prostate Cancer by 27 companies/universities/institutes. The top development phase for Hormone-Sensitive Prostate Cancer is phase ii with 16 drugs in that stage. The Hormone-Sensitive Prostate Cancer pipeline has 29 drugs in development by companies and five by universities/ institutes. Some of the companies in the Hormone-Sensitive Prostate Cancer pipeline products market are: Jiangsu Hengrui Medicine, AstraZeneca and Bristol-Myers Squibb.
The key targets in the Hormone-Sensitive Prostate Cancer pipeline products market include Androgen Receptor, Glutamate Carboxypeptidase 2, and Steroid 17 Alpha Hydroxylase/17,20 Lyase.
The key mechanisms of action in the Hormone-Sensitive Prostate Cancer pipeline product include Androgen Receptor Antagonist with five drugs in Phase III. The Hormone-Sensitive Prostate Cancer pipeline products include ten routes of administration with the top ROA being Oral and five key molecule types in the Hormone-Sensitive Prostate Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Hormone-Sensitive Prostate Cancer overview
Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they continue to grow despite low or undetectable levels of androgens. Hormone therapy for HSPC can slow down the progression of the disease and improve survival outcomes. However, hormone therapy can also cause side effects such as hot flashes, sexual dysfunction, bone loss, fatigue, and mood changes. Therefore, patients with HSPC should discuss the benefits and risks of hormone therapy with their doctors and consider their quality of life and personal preferences when choosing a treatment option.
For a complete picture of Hormone-Sensitive Prostate Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
